Spotlight ''Pregabalin (Lyrica° Or Other Brands) And Gabapentin ...

{1} ##LOC[OK]## {1} ##LOC[OK]## ##LOC[Cancel]## {1} ##LOC[OK]## ##LOC[Cancel]##

Register online | Log in | My Prescrire

Issue contents

• Current issue
• Last 12 issues
• All issues

Topics

• Annual Prescrire Awards
• Advancing healthcare policy
• Positions
• Mediator° - the criminal trial
• Drugs to avoid: 2025 update
• Spotlight

About Prescrire

• Editorial policies
• How we work
• AMP: non-profit
• Financing
• No conflicts of interest
• Where to find us
• About Prescrire International
• Citations in other journals
• A global network

Offers

• Subscribe or renew my subscription
• Solidarity Subscription Rate
• Subscribers: register online
• Prescrire's other products
• Free Special Edition
• Sign up to receive the newsletter

english.prescrire.org > Spotlight > 100 most recent > Pregabalin (Lyrica° or other brands) and gabapentin (Neurontin° or other brands): known dangers and uncertainties during pregnancy Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent : 1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Spotlight

• 100 most recent
• Archives

Pregabalin (Lyrica° or other brands) and gabapentin (Neurontin° or other brands): known dangers and uncertainties during pregnancy Taken during pregnancy, pregabalin and gabapentin expose the newborn to harmful effects. Pregabalin and gabapentin are two very similar drugs which are widely used in France, particularly as antiepileptics and to treat neuropathic pain. Taking these drugs during pregnancy exposes unborn children to various known and unknown harms, some of them potentially severe. In the case of in utero exposure to pregabalin during the first trimester of pregnancy, major malformations are about three times more frequent than in unexposed children. A French study of some 1,700 children exposed in utero showed malformations of the aorta and skull. Smaller-scale studies on gabapentin do not rule out an increased risk of major malformations. Children exposed in utero to pregabalin or gabapentin in the second and third trimesters of pregnancy were found to have a higher incidence of preterm birth, low birth weight, signs of drug toxicity (drowsiness, difficulty sucking, diarrhoea), withdrawal symptoms and admission to a neonatal intensive care unit. In the long term, mental and behavioural disorders are more frequent after in utero exposure to pregabalin than in unexposed children. The data on gabapentin is too scant to rule out this risk. In practice, pregabalin and gabapentin should be avoided whenever possible in women who are or could become pregnant. However, when either of these drugs is chosen during pregnancy, it is important to inform the woman of its known risks and uncertainties. If used close to delivery, it is useful to inform the delivery team so that the neonate receives the necessary monitoring. ©Prescrire 1 May 2020 "Pregabalin or gabapentin during pregnancy: take their known dangers and uncertainties into account" Prescrire Int 2020; 29 (215): 127-129. (Pdf, subscribers only). Share

Share

Download the full review. Pdf, subscribers only Antiepileptics and pregnancy: potential long-term effects in children Prescrire Int 2020 ; 29 (211) : 13-20. Pdf, subscribers only Short-term effects of in utero exposure to antiepileptics other than valproic acid Prescrire Int 2020 ; 29 (211) : 16-17. Pdf, subscribers only

• Sitemap |
• Terms of use |
• Contact
• |Top of page

Prescrire

Your change of address has been received and will be processed promptly but will not appear instantaneously

Prescrire

Your message has been sent

The Prescrire website uses cookies. These cookies are used to optimise navigation, to measure site traffic, to offer videos online, and to allow subscribers to access the content they are entitled to as subscribers.

> Manage my choices Accept all cookies > Close

Manage my choices

When you visit the Prescrire website, cookies are stored on your web browser. Some of these cookies require your consent. You can either accept or reject various types of cookies below. In order to benefit from the best online experience (access to subscriber-only content, online videos, optimisation of online content via analysis of site traffic, sharing of articles via social media, etc.), we recommend that you accept all of these types of cookies.

Accept all cookies Reject non-essential cookies

Essential cookies

Active

These cookies allow the website to function, and allow its content to be optimised. This includes cookies enabling subscribers to log in and to access subscriber-only content. Cookies from the Vimeo video platform are also essential for users to access video content online on the site, and for Prescrire to anonymously measure traffic for its videos. These cookies are necessary for the website to function properly.

Statistical cookies

Reject Active

Cookies from Google Analytics are used to generate anonymous statistics, in order to measure the website's traffic, and to optimise the site's usability, organisation and content. This data is not used for advertising purposes.

Social media cookies

Reject Active

These cookies allow users to share the website's content via social media, including Facebook and Twitter. If you reject these cookies, you will not be able to share articles from the Prescrire website via social media.

Confirm